State and territory governments, in conjunction with the Therapeutic Goods Administration (TGA), will determine which patient groups will receive access to medicinal cannabis products and what medicinal cannabis products can be manufactured.
Guidance
The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development new clinical guidance documents for prescribers of medicinal cannabis products for treating chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic non-cancer pain and palliative care, as well as an overview document.
For patients
- Medicinal cannabis products: Patient information (overview)
- Guidance for the use of medicinal cannabis in Australia: Patient information
For prescribers
- Guidance for the use of medicinal cannabis in Australia: Overview
- Guidance for the use of medicinal cannabis in the treatment of multiple sclerosis in Australia
- Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia
- Guidance for the use of medicinal cannabis in the treatment of epilepsy in paediatric and young adult patients in Australia
- Guidance for the use of medicinal cannabis for the prevention or management of nausea and vomiting in Australia
- Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia
A series of reviews of the evidence around the potential use of medicinal cannabis products in the following conditions is being undertaken, some of which are complete and available on the TGA website:
- Paediatric and adult epilepsies
- Multiple sclerosis
- Nausea and vomiting, resulting from chemotherapy and HIV/AIDS therapy
- Various types of pain
- Palliative care
Find out more in the patient access section of this website or see the Access to medicinal cannabis products web page on the TGA website.